64,715 Shares of Danaher Corporation $DHR Bought by Schaper Benz & Wise Investment Counsel Inc. WI

Schaper Benz & Wise Investment Counsel Inc. WI bought a new stake in shares of Danaher Corporation (NYSE:DHR) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 64,715 shares of the conglomerate’s stock, valued at approximately $14,338,000.

Several other large investors have also added to or reduced their stakes in DHR. BlackRock Inc. bought a new stake in Danaher in the second quarter worth approximately $10,492,520,000. Jupiter Topco LLC acquired a new stake in shares of Danaher during the 2nd quarter worth approximately $1,456,317,000. Generation Investment Management LLP bought a new stake in shares of Danaher in the 2nd quarter valued at $1,287,949,000. Bank of America Corp DE bought a new stake in shares of Danaher in the 2nd quarter valued at $993,846,000. Finally, Legal & General Group Plc acquired a new position in shares of Danaher during the 2nd quarter valued at $801,056,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the topic of several research analyst reports. Guggenheim increased their target price on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Evercore reiterated an “outperform” rating and set a $230.00 price objective on shares of Danaher in a report on Monday, July 6th. UBS Group began coverage on shares of Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective on the stock. TD Cowen decreased their target price on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, Royal Bank Of Canada upped their price target on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $235.23.

Danaher Stock Performance

DHR opened at $220.15 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company’s fifty day moving average price is $211.38 and its two-hundred day moving average price is $194.62. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a market cap of $154.76 billion, a price-to-earnings ratio of 39.10, a PEG ratio of 2.71 and a beta of 0.76.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business’s revenue was up 5.5% on a year-over-year basis. During the same period last year, the company earned $0.77 earnings per share. On average, analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.